rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2012-8-3-457-462rpcardio-470Research ArticlePOINT OF VIEWТОЧКА ЗРЕНИЯTHE PROBLEM OF THE OPTIMAL PHARMACOTHERAPY CHOICE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASEПРОБЛЕМА ВЫБОРА ОПТИМАЛЬНОЙ ЛЕКАРСТВЕННОЙ ТЕРАПИИ У БОЛЬНЫХ СО СТАБИЛЬНЫМ ТЕЧЕНИЕМ ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦАГиляревскийС. Р.GilyarevskiyS. R.

д.м.н., профессор, руководитель 3 кардиологического отделения для больных инфарктом миокарда НИИ СП им Н.В. Склифосовского

sgilarevsky@rambler.ruОрловВ. А.OrlovV. A.

д.м.н., профессор, заведующий кафедрой клинической фармакологии и терапии РМАПО

КузьминаИ. М.Kuz'minaI. M.

к.м.н., ведущий научный сотрудник 3 кардиологического отделения для больных инфарктом миокарда НИИ СП им Н.В. Склифосовского

НИИ скорой помощи им. Н.В. СклифосовскогоРоссияResearch Institute of Emergency Medicine named after N.V. SklifosovskyRussian FederationРоссийская медицинская академия последипломного образованияРоссияRussian Medical Academy of Postgraduate EducationRussian Federation20120201201683457462Copyright © Gilyarevskiy S.R., Orlov V.A., Kuz'mina I.M., 20152015Гиляревский С.Р., Орлов В.А., Кузьмина И.М.Gilyarevskiy S.R., Orlov V.A., Kuz'mina I.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/470

The problem of the "optimal pharmacotherapy" choice in patients with stable coronary artery disease is discussed. Expert’s opinions are presented concerning first-line antiischemic drugs and about current approaches to the choosing additional (adjuvant) antiischemic drugs. The practical application of optimal pharmacotherapy in patients with stable angina pectoris is also discussed.

Обсуждается проблема выбора оптимальной лекарственной терапии при лечении больных со стабильным течением ИБС. Приводится мнение экспертов относительно противоишемических препаратов первого ряда, о современных подходах к выбору дополнительных противоишемических препаратов. Также обсуждается практическое применение оптимальной лекарственной терапии у больных со стабильной стенокардией.

оптимальная лекарственная терапияишемическая болезнь сердцаoptimal pharmacotherapycoronary heart diseaseReferencesThe management of stable angina. NICE clinical guideline 126, published on 27 July 2011. Available at: http://www.nice.org.uk/nicemedia/live/13549/55660/55660.pdf. Date of access: 15.06.2012.The management of stable angina. NICE clinical guideline 126, published on 27 July 2011. Available at: http://www.nice.org.uk/nicemedia/live/13549/55660/55660.pdf. Date of access: 15.06.2012.Henderson R.A., O'Flynn N. Guideline Development Group. Management of stable angina: summary of NICE guidance. Heart 2012;98:500–507.Henderson R.A., O'Flynn N. Guideline Development Group. Management of stable angina: summary of NICE guidance. Heart 2012;98:500–507.Sculpher M.J., Petticrew M., Kelland J.L., et al. Resource allocation for chronic stable angina: a systematic review of effectiveness, costs and cost-effectiveness of alternative interventions. Health Technol Assess 1998;2:1e175.Sculpher M.J., Petticrew M., Kelland J.L., et al. Resource allocation for chronic stable angina: a systematic review of effectiveness, costs and cost-effectiveness of alternative interventions. Health Technol Assess 1998;2:1e175.Scottish Intercollegiate Guidelines Network. Management of Stable Angina. Edinburgh: NHS Quality Improvement Scotland; 2007.Scottish Intercollegiate Guidelines Network. Management of Stable Angina. Edinburgh: NHS Quality Improvement Scotland; 2007.Fox K.M., Garcia M.A., Ardissino D. Guidelines on the management of stable angina pectoris. Eur Heart J 2006;27:1341–1381.Fox K.M., Garcia M.A., Ardissino D. Guidelines on the management of stable angina pectoris. Eur Heart J 2006;27:1341–1381.von Arnim T. Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. J Am Coll Cardiol 1995; 25:231–238.von Arnim T. Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. J Am Coll Cardiol 1995; 25:231–238.van Dijk R.B., Lie K.I., Crijns H.J. Diltiazem in comparison with metoprolol in stable angina pectoris. Eur Heart J 1988;9:1194–1199.van Dijk R.B., Lie K.I., Crijns H.J. Diltiazem in comparison with metoprolol in stable angina pectoris. Eur Heart J 1988;9:1194–1199.O'Hara M.J., Khurmi N.S., Bowles M.J., et al. Diltiazem and propranolol combination for the treatment of chronic stable angina pectoris. Clin Cardiol 1987;10:115–123.O'Hara M.J., Khurmi N.S., Bowles M.J., et al. Diltiazem and propranolol combination for the treatment of chronic stable angina pectoris. Clin Cardiol 1987;10:115–123.Kawanishi D.T., Reid C.L., Morrison E.C., et al. Response of angina and ischemia to long-term treatment in patients with chronic stable angina: a double-blind randomized individualized dosing trial of nifedipine, propranolol and their combination. J Am Coll Cardiol 1992;19:409–417.Kawanishi D.T., Reid C.L., Morrison E.C., et al. Response of angina and ischemia to long-term treatment in patients with chronic stable angina: a double-blind randomized individualized dosing trial of nifedipine, propranolol and their combination. J Am Coll Cardiol 1992;19:409–417.Savonitto S., Ardissiono D., Egstrup K., et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol 1996;27:311–316.Savonitto S., Ardissiono D., Egstrup K., et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol 1996;27:311–316.Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., et al. A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805–2816.Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., et al. A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805–2816.Rehnqvist N., Hjemdahl P., Billing E., et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996; 17:76–81.Rehnqvist N., Hjemdahl P., Billing E., et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996; 17:76–81.Dargie H.J., Ford I, Fox K.M. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J 1996;17:104–112.Dargie H.J., Ford I, Fox K.M. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J 1996;17:104–112.Hjemdahl P., Eriksson S.V., Held C., et al. Favourable long term prognosis in stable angina pectoris: an extended follow up of the Angina Prognosis Study in Stockholm (APSIS). Heart 2006;92:177–182.Hjemdahl P., Eriksson S.V., Held C., et al. Favourable long term prognosis in stable angina pectoris: an extended follow up of the Angina Prognosis Study in Stockholm (APSIS). Heart 2006;92:177–182.Shu D.F., Dong B.R., Lin X.F., et al. Long-term beta blockers for stable angina: systematic review and meta-analysis. Eur J Cardiovasc Prev Rehabil 2012;19:330–341.Shu D.F., Dong B.R., Lin X.F., et al. Long-term beta blockers for stable angina: systematic review and meta-analysis. Eur J Cardiovasc Prev Rehabil 2012;19:330–341.Daly C.A., Clemens F., Sendon J.L.L., et al. The initial management of stable angina in Europe, from the Euro Heart Survey. Eur Heart J 2005;26:1011–1022.Daly C.A., Clemens F., Sendon J.L.L., et al. The initial management of stable angina in Europe, from the Euro Heart Survey. Eur Heart J 2005;26:1011–1022.de Vries R.J., Dunselman P.H., van Veldhuisen D.J., et al. Comparison between felodipine and isosor-bide mononitrate as adjunct to beta blockade in patients >65 years of age with angina pectoris. Am J Cardiol 1994;74:1201–1206.de Vries R.J., Dunselman P.H., van Veldhuisen D.J., et al. Comparison between felodipine and isosor-bide mononitrate as adjunct to beta blockade in patients >65 years of age with angina pectoris. Am J Cardiol 1994;74:1201–1206.Gori T., Parker J.D. Nitrate-induced toxicity and preconditioning: a rationale for reconsidering the use of these drugs. J Am Coll Cardiol 2008;52:251–254.Gori T., Parker J.D. Nitrate-induced toxicity and preconditioning: a rationale for reconsidering the use of these drugs. J Am Coll Cardiol 2008;52:251–254.DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res 2006;53:399–406.DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res 2006;53:399–406.Savelieva I., Camm A.J. If inhibition with ivabradine: electrophysiological effects and safety. Drug Saf 2008;31:95–107.Savelieva I., Camm A.J. If inhibition with ivabradine: electrophysiological effects and safety. Drug Saf 2008;31:95–107.Tardif J.C., Ford I., Tendera M., et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005;26:2529–2536.Tardif J.C., Ford I., Tendera M., et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005;26:2529–2536.Ruzyllo W., Tendera M., Ford I., et al. Antianginal efficacy and safety of ivabradine compared with am-lodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multi-centre, noninferiority trial. Drugs 2007;67:393–405.Ruzyllo W., Tendera M., Ford I., et al. Antianginal efficacy and safety of ivabradine compared with am-lodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multi-centre, noninferiority trial. Drugs 2007;67:393–405.Tardif J.C., Ponikowski P., Kahan T., et al. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009;30:540–548.Tardif J.C., Ponikowski P., Kahan T., et al. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009;30:540–548.Meeter K., Kelder J.C., Tijssen J.G., et al. Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: a long-term, double-blind, randomized study. J Cardiovasc Pharmacol 1992;(20 Suppl 3):S59–66.Meeter K., Kelder J.C., Tijssen J.G., et al. Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: a long-term, double-blind, randomized study. J Cardiovasc Pharmacol 1992;(20 Suppl 3):S59–66.Ulvenstam G., Diderholm E., Frithz G., et al. Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, ran-domized, multicenter study. J Cardiovasc Pharmacol 1992;(20 Suppl 3):S67–73.Ulvenstam G., Diderholm E., Frithz G., et al. Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, ran-domized, multicenter study. J Cardiovasc Pharmacol 1992;(20 Suppl 3):S67–73.Guermonprez J.L., Blin P., Peterlongo F. A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris. Eur Heart J 1993;14(Suppl B):S30–34.Guermonprez J.L., Blin P., Peterlongo F. A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris. Eur Heart J 1993;14(Suppl B):S30–34.Chatterjee T., Fleisch M., Meier B., et al. Comparison of the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study. J Clin Basic Cardiol 1999;2:213–217.Chatterjee T., Fleisch M., Meier B., et al. Comparison of the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study. J Clin Basic Cardiol 1999;2:213–217.IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002;359:1269–1275.IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002;359:1269–1275.Chaitman B.R., Pepine C.J., Parker J.O., et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004;291:309–316.Chaitman B.R., Pepine C.J., Parker J.O., et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004;291:309–316.Stone P.H., Gratsiansky N.A., Blokhin A., et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006;48:566–575.Stone P.H., Gratsiansky N.A., Blokhin A., et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006;48:566–575.Szwed H., Sadowski Z., Elikowski W., et al. Combination treatment in stable effort angina using trimetazi-dine and metoprolol: results of a randomized, double-blind, multicenter study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 2001;22:2267—2274.Szwed H., Sadowski Z., Elikowski W., et al. Combination treatment in stable effort angina using trimetazi-dine and metoprolol: results of a randomized, double-blind, multicenter study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 2001;22:2267—2274.Chazov E.I., Lepakchin V.K., Zharova E.A., et al. Trimetazidine in Angina Combination Therapy--the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther 2005;12:35—42.Chazov E.I., Lepakchin V.K., Zharova E.A., et al. Trimetazidine in Angina Combination Therapy--the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther 2005;12:35—42.Herman M., Donovan J., Tran M., et al. Use of beta-blockers and effects on heart rate and blood pressure post-acute coronary syndromes: are we on target? Am Heart J 2009;158:378–385.Herman M., Donovan J., Tran M., et al. Use of beta-blockers and effects on heart rate and blood pressure post-acute coronary syndromes: are we on target? Am Heart J 2009;158:378–385.Jabbour A., Macdonald P.S., Keogh A.M., et al. Differences Between Beta-Blockers in Patients With Chronic Heart Failure and Chronic Obstructive Pulmonary Disease J Am Coll Cardiol 2010;55:1780– 1787.Jabbour A., Macdonald P.S., Keogh A.M., et al. Differences Between Beta-Blockers in Patients With Chronic Heart Failure and Chronic Obstructive Pulmonary Disease J Am Coll Cardiol 2010;55:1780– 1787.Yusuf S., Islam S., Chow C.K., et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378:1231–1243.Yusuf S., Islam S., Chow C.K., et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378:1231–1243.Haas J.S., Phillips K.A., Gerstenberger E.P., Seger A.C. Potential Savings from Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 1997–2000. Ann Intern Med 2005;142:891–897.Haas J.S., Phillips K.A., Gerstenberger E.P., Seger A.C. Potential Savings from Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 1997–2000. Ann Intern Med 2005;142:891–897.Martsevich S.Yu., Kutishenko N.P., Ginzburg M.L. The KARDIOKANON study: a way to settle the subject of clinical equivalence of generic and original drugs. Rational Pharmacother Card 2012;8(2):179–184. Russian (Марцевич С.Ю., Кутишенко Н.П., Гинзбург М.Л., и др. Исследование КАРДИОКАНОН: способ решения вопроса о клинической эквивалентности оригинальных и воспроизведенных препаратов. Рациональная Фармакотерапия в Кардиологии 2012;8(2):179–184).Martsevich S.Yu., Kutishenko N.P., Ginzburg M.L. The KARDIOKANON study: a way to settle the subject of clinical equivalence of generic and original drugs. Rational Pharmacother Card 2012;8(2):179–184. Russian (Марцевич С.Ю., Кутишенко Н.П., Гинзбург М.Л., и др. Исследование КАРДИОКАНОН: способ решения вопроса о клинической эквивалентности оригинальных и воспроизведенных препаратов. Рациональная Фармакотерапия в Кардиологии 2012;8(2):179–184).

The authors declare that there are no conflicts of interest present.